Bristol-Myers Squibb Company / Case Study / NIAID AIDS Clinical Trials Group / CDC / New HIV Infections / Immune Deficiency Syndrome / Bristol-Myers Squibb / /
Country
United States / /
Event
M&A / FDA Phase / /
Facility
National Institute of Allergy / National Cancer Institute / /
IndustryTerm
immune systems / technology transfer challenge / HIV Prevention / clinical trial network / HIV therapy / treatment of HIV / /
MedicalCondition
New HIV Infections / TB / HIV / herpes / hepatitis C / symptomatic HIV infection / viral diseases / influenza / HIV infection / HIV Infection HAART / Cancer / disease / chronic illness / Immune Deficiency Syndrome / AIDS / HIV disease / /
MedicalTreatment
Anti-retroviral Therapy / HAART / /
Organization
National Cancer Institute / National Institute of Health / World Health Organization / Food and Drug Administration / NIH National Institutes of Health office of Technology Transfer Page / Infectious Diseases / National Institute of Allergy and Infectious Diseases / National Institute of Allergy / NIH office of Technology Transfer / UNAIDS / /
Person
Sam Broder / Hiroaki Mitsuya / Robert Yarchoan / Dale Shoemaker / Jonathan Kagan / /
Product
zidovudine / Videx / HIV / didanosine / Videx® Expanding Possibilities / free drug / Videx® / /
VitraveneTM, Innovation in Medicine: A Case Study